Related Experiment Videos
[Polymyositis and dermatomyositis in childhood]
A Rodríguez Núñez1, J M Fernández Bustillo, E Rodríguez Pérez
1Departamento de Pediatría, Hospital General de Galicia, Facultad de Medicina, Universidad de Santiago de Conpostela.
Anales Espanoles De Pediatria
|October 1, 1988
Summary
Juvenile polymyositis-dermatomyositis is a rare autoimmune disease affecting children. Early prednisone treatment is effective for most, while some require advanced therapies like methotrexate for chronic cases.
Area of Science:
- Pediatric Rheumatology
- Autoimmune Diseases
- Clinical Research
Context:
- Juvenile polymyositis-dermatomyositis (JPDM) is a rare autoimmune condition affecting children.
- This study focuses on the clinical presentation, treatment, and outcomes of JPDM.
- Understanding JPDM is crucial for timely diagnosis and effective management in pediatric patients.
Purpose:
- To report clinical and laboratory findings in children diagnosed with JPDM.
- To describe the treatment strategies and patient evolution over a seven-year period.
- To evaluate the efficacy of initial and advanced therapeutic interventions for JPDM.
Summary:
- The study analyzed nine children (six girls, three boys) aged 20 months to 13 years with JPDM.
- Presenting symptoms included fatigue and proximal muscle weakness, with skin lesions in three cases.
- Initial treatment with prednisone showed favorable responses in seven patients; two with chronic disease received methotrexate and IV methylprednisolone.
Impact:
- Highlights the effectiveness of initial prednisone therapy for JPDM.
- Provides insights into managing chronic or refractory JPDM cases.
- Contributes to the understanding of JPDM's clinical course and therapeutic responses in children.